Report Overview

China Sacroglycanopathies Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Sacroglycanopathiesare formsof limb-girdlemusculardystrophycaused by mutations in the SGCA, SGCB, SGCG, and SGCD genes. Limb-girdle muscular dystrophies (LGMD) are a group of rare progressive genetic disorders that are characterized by wasting (atrophy) and weakness of the voluntary muscles of the hip and shoulder areas (limb-girdle area). LGMD2C-2F are called sacroglycanopathies. The global prevalence of sacroglycanopathies is 1 in 1,20,000 persons.



Market Drivers

China is a growing market for sacroglycanopathies due to factors such as increase in global prevalence rate (estimated, 1 in 1,20,000). In addition to this the other factors that contribute to the growth of the market are rise in healthcare expenditure and increase in R&D activities by private players.

However, there are some restraining factors for growth of sacroglycanopathies therapeutics market in China such as undiagnosed or misdiagnosed, lack of novel therapeutics for the treatment.